Market Place
Sourcing Support
Epicentrx Adapt-001 Oral Presentation: Advanced Tgf? Trap At Asco 2024
23 May 2024 //
PR NEWSWIRE
USAN Council & INN Expert Committee Recognizes New Therapeutic nibrozetone
06 Jul 2023 //
PR NEWSWIRE
EpicentRx Presents Updates on its Oncology Clinical Development Programs at ASCO
02 Jun 2023 //
PR NEWSWIRE
EpicentRx Receives Fast Track Designation from U.S. FDA for Lead Asset, RRx-001
29 Mar 2023 //
PR NEWSWIRE
EpicentRx makes case for cancer toxicity prevention drug
20 Jan 2023 //
FIERCE BIOTECH
EpicentRx to Present for PII Trial to Assess Efficacy of RRx-001 vs. regorafenib
20 Jan 2023 //
PR NEWSWIRE
EpicentRx Publishes Phase 2 Results for RRx-001 as an Anti-Mucositis Agent
19 Jan 2023 //
PR NEWSWIRE
RRx-001 + Irinotecan Significantly Improved PFS Versus Regorafenib in PII Trial
14 Dec 2022 //
PRNEWSWIRE
EpicentRx Announces Patent Issued for Radiation Protection with RRx-001
06 Dec 2022 //
PRNEWSWIRE
EpicentRx Awarded Funding from FightMND to Evaluate Potential of RRx-001
29 Nov 2022 //
PRNEWSWIRE
EpicentRx Announces Presentations Focusing on RRx-001 Inhibition
10 Nov 2022 //
PRNEWSWIRE
EpicentRx doses first subject in Phase III lung cancer trial in China
07 Oct 2022 //
CLINICALTRIALSARENA
EpicentRx Publishes Commentary in IJID on Need for a "Universal" COVID Vaccine
03 Aug 2022 //
PRNEWSWIRE
EpicentRx Awarded Grant from Michael J. Fox Foundation to Evaluate RRx-001 in PD
12 Jul 2022 //
PRNEWSWIRE
EpicentRx Announces Poster Presentation for PII Randomized Trial with RRx-001
01 Jun 2022 //
PRNEWSWIRE
EpicentRx begins Phase I trial of paediatric CNS tumour treatment
25 Feb 2022 //
CLINICALTRIALSARENA
EpicentRx and Texas Children`s Cancer Center Initiate Phase 1 Trial with RRx-001
23 Feb 2022 //
PRNEWSWIRE
EpicentRx Granted New Composition of Matter Patent for TGF-ß Trap Fusion Protein
22 Nov 2021 //
PRNEWSWIRE
EpicentRx & SciClone Pharmaceuticals Establish Licensing Agreement for RRx-001
01 Jul 2020 //
PRNEWSWIRE
EpicentRx IND Application for Second Immuno-oncology Program, a TGF-? Trap
03 Mar 2020 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.